nucresiran   Click here for help

GtoPdb Ligand ID: 14726

Synonyms: ALN-TTRsc04
Compound class: Nucleic acid
Comment: Nucresiran (ALN-TTRsc04) is a small interfering RNA (siRNA) that is designed to target transthyretin (TTR) mRNA to reduce TTR expression. To improve pharmacokinetics, the nucleotides are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone, and it has a N-acetylgalactosamine (GalNAc) modified forward strand 5' end ("R" in the sequence provided) to enhance hepatic delivery via binding to liver-expressed asialoglycoprotein receptors (ASGRs).
No information available.
Summary of Clinical Use Click here for help
Nucresiran was progressed as a clinical candidate for its potential to treat hereditary transthyretin-mediated amyloidosis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05661916 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects Phase 1 Interventional Alnylam Pharmaceuticals
NCT07052903 TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Phase 3 Interventional Alnylam Pharmaceuticals
NCT07223203 TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Phase 3 Interventional Alnylam Pharmaceuticals